Published in Br J Pharmacol on October 01, 2005
Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol (2008) 5.32
Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev (2008) 3.51
Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol (2009) 2.82
Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry (2006) 2.01
Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol (2006) 1.83
Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br J Pharmacol (2006) 1.77
The endocannabinoid system and pain. CNS Neurol Disord Drug Targets (2009) 1.59
The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings. Inflammopharmacology (2013) 1.56
Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology (Berl) (2007) 1.53
Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain. J Pharmacol Exp Ther (2011) 1.52
The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J (2005) 1.50
Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther (2008) 1.45
Structure-guided inhibitor design for human FAAH by interspecies active site conversion. Proc Natl Acad Sci U S A (2008) 1.41
Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br J Pharmacol (2007) 1.39
Lack of selectivity of URB602 for 2-oleoylglycerol compared to anandamide hydrolysis in vitro. Br J Pharmacol (2006) 1.36
Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation. AAPS J (2009) 1.36
Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br J Pharmacol (2007) 1.28
Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders. Expert Opin Drug Discov (2009) 1.22
The inhibition of monoacylglycerol lipase by URB602 showed an anti-inflammatory and anti-nociceptive effect in a murine model of acute inflammation. Br J Pharmacol (2007) 1.18
Regulation of inflammatory pain by inhibition of fatty acid amide hydrolase. J Pharmacol Exp Ther (2010) 1.16
The contribution of cyclooxygenase-2 to endocannabinoid metabolism and action. Br J Pharmacol (2007) 1.14
Inhibition of fatty acid amide hydrolase produces PPAR-alpha-mediated analgesia in a rat model of inflammatory pain. Br J Pharmacol (2008) 1.14
A decrease in anandamide signaling contributes to the maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain. J Neurosci (2008) 1.13
Evaluation of fatty acid amides in the carrageenan-induced paw edema model. Neuropharmacology (2007) 1.11
Crystal structure of fatty acid amide hydrolase bound to the carbamate inhibitor URB597: discovery of a deacylating water molecule and insight into enzyme inactivation. J Mol Biol (2010) 1.09
TASK1 modulates inflammation and neurodegeneration in autoimmune inflammation of the central nervous system. Brain (2009) 1.09
Potential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents. Br J Pharmacol (2009) 1.07
The neuroprotective impact of the leak potassium channel TASK1 on stroke development in mice. Neurobiol Dis (2008) 1.02
The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice. Br J Pharmacol (2012) 1.01
Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain. Nat Rev Drug Discov (2012) 0.99
Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice. Pharmacol Biochem Behav (2011) 0.98
O-hydroxyacetamide carbamates as a highly potent and selective class of endocannabinoid hydrolase inhibitors. ACS Chem Neurosci (2011) 0.94
Lack of effect of chronic pre-treatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: evidence for plastic changes in the endocannabinoid system. Br J Pharmacol (2012) 0.93
Inhibitory effects of traditional herbal formula pyungwi-san on inflammatory response in vitro and in vivo. Evid Based Complement Alternat Med (2013) 0.89
The 'specific' tyrosine kinase inhibitor genistein inhibits the enzymic hydrolysis of anandamide: implications for anandamide uptake. Br J Pharmacol (2007) 0.88
The structure of monoacylglycerol lipase from Bacillus sp. H257 reveals unexpected conservation of the cap architecture between bacterial and human enzymes. Biochim Biophys Acta (2012) 0.88
Interaction of ligands for the peroxisome proliferator-activated receptor gamma with the endocannabinoid system. Br J Pharmacol (2007) 0.87
Inhibition of fatty acid amide hydrolase by kaempferol and related naturally occurring flavonoids. Br J Pharmacol (2008) 0.87
A Cannabinoid CB1 Receptor-Positive Allosteric Modulator Reduces Neuropathic Pain in the Mouse with No Psychoactive Effects. Neuropsychopharmacology (2015) 0.87
Characterization of the effects of reuptake and hydrolysis inhibition on interstitial endocannabinoid levels in the brain: an in vivo microdialysis study. ACS Chem Neurosci (2012) 0.86
Effects of endocannabinoid neurotransmission modulators on brain stimulation reward. Psychopharmacology (Berl) (2006) 0.86
A binding site for nonsteroidal anti-inflammatory drugs in fatty acid amide hydrolase. J Am Chem Soc (2012) 0.86
Augmentation of endogenous cannabinoid tone modulates lipopolysaccharide-induced alterations in circulating cytokine levels in rats. Immunology (2008) 0.85
Biochanin A, a naturally occurring inhibitor of fatty acid amide hydrolase. Br J Pharmacol (2010) 0.83
Inhibition of monoacylglycerol lipase by troglitazone, N-arachidonoyl dopamine and the irreversible inhibitor JZL184: comparison of two different assays. Br J Pharmacol (2010) 0.82
Pharmacological blockade of the fatty acid amide hydrolase (FAAH) alters neural proliferation, apoptosis and gliosis in the rat hippocampus, hypothalamus and striatum in a negative energy context. Front Cell Neurosci (2015) 0.80
Experimental cannabinoid 2 receptor-mediated immune modulation in sepsis. Mediators Inflamm (2014) 0.79
The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain. Neuropsychopharmacology (2017) 0.78
Full Fatty Acid Amide Hydrolase Inhibition Combined with Partial Monoacylglycerol Lipase Inhibition: Augmented and Sustained Antinociceptive Effects with Reduced Cannabimimetic Side Effects in Mice. J Pharmacol Exp Ther (2015) 0.78
Clickable, photoreactive inhibitors to probe the active site microenvironment of fatty acid amide hydrolase(). Chem Sci (2011) 0.78
Chemical synthesis, pharmacological characterization, and possible formation in unicellular fungi of 3-hydroxy-anandamide. J Lipid Res (2008) 0.77
Safety, Tolerability and Pharmacokinetics of FAAH Inhibitor V158866: A Double-Blind, Randomised, Placebo-Controlled Phase I Study in Healthy Volunteers. Drugs R D (2016) 0.77
Endocannabinoid modulation by FAAH and monoacylglycerol lipase within the analgesic circuitry of the periaqueductal grey. Br J Pharmacol (2014) 0.77
sec-Butylpropylacetamide (SPD), a New Amide Derivative of Valproic Acid for the Treatment of Neuropathic and Inflammatory Pain. Pharmacol Res (2016) 0.76
Inhibition of FAAH, TRPV1, and COX2 by NSAID-serotonin conjugates. Bioorg Med Chem Lett (2014) 0.76
Inhibition of endocannabinoid metabolism by the metabolites of ibuprofen and flurbiprofen. PLoS One (2014) 0.76
Dual-Acting Compounds Targeting Endocannabinoid and Endovanilloid Systems-A Novel Treatment Option for Chronic Pain Management. Front Pharmacol (2016) 0.75
Mustard vesicants alter expression of the endocannabinoid system in mouse skin. Toxicol Appl Pharmacol (2016) 0.75
A chemical genetic screen uncovers a small molecule enhancer of the N-acylethanolamine degrading enzyme, fatty acid amide hydrolase, in Arabidopsis. Sci Rep (2017) 0.75
Interactions of Cannabinoids With Biochemical Substrates. Subst Abuse (2017) 0.75
Inhibition of Endocannabinoid-Metabolizing Enzymes in Peripheral Tissues Following Developmental Chlorpyrifos Exposure in Rats. Int J Toxicol (2017) 0.75
Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 13.45
Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature (1999) 10.05
Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med (2002) 7.72
Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol (1988) 5.54
Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem (1997) 3.55
The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol (2004) 3.38
SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther (1998) 3.20
Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther (2004) 3.14
Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther (2004) 2.99
Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol (1993) 2.98
Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain (2004) 2.94
The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest (2004) 2.52
Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity. Gastroenterology (1998) 2.46
The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J Med Chem (2005) 2.34
Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. J Exp Med (1996) 2.28
Functional disassociation of the central and peripheral fatty acid amide signaling systems. Proc Natl Acad Sci U S A (2004) 2.23
A newly identified role for superoxide in inflammatory pain. J Pharmacol Exp Ther (2004) 2.21
Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. J Biol Chem (2001) 2.19
Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2. J Biol Chem (1997) 2.18
Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Lett (1998) 2.16
Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. J Med Chem (2004) 2.05
Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors. Am J Physiol Heart Circ Physiol (2004) 1.88
Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol (2001) 1.67
Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology (2003) 1.60
CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain (2002) 1.55
Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation. Eur J Pharmacol (2004) 1.50
Therapeutic potential of cannabinoids in CNS disease. CNS Drugs (2003) 1.44
Involvement of vanilloid receptor VR1 and prostanoids in the acid-induced writhing responses of mice. Life Sci (2001) 1.42
Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts. Br J Pharmacol (2002) 1.41
Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J Neurosci (2002) 1.40
Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br J Pharmacol (2002) 1.40
Defective adult neurogenesis in CB1 cannabinoid receptor knockout mice. Mol Pharmacol (2004) 1.34
In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. J Pharmacol Exp Ther (2001) 1.31
Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot Essent Fatty Acids (2002) 1.29
A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. Pain (2003) 1.25
The endocannabinoid signalling system: biochemical aspects. Pharmacol Biochem Behav (2005) 1.25
Massive accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia? J Neurochem (2004) 1.24
The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. Biochem J (1998) 1.23
A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J (2004) 1.21
A simple stopped assay for fatty acid amide hydrolase avoiding the use of a chloroform extraction phase. J Biochem Biophys Methods (2004) 1.19
Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents. Br J Pharmacol (2003) 1.15
Cannabinoids and multiple sclerosis. Pharmacol Ther (2002) 1.12
A role for endocannabinoids in indomethacin-induced spinal antinociception. Eur J Pharmacol (2002) 1.10
Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br J Pharmacol (2004) 1.09
The uterus is a potential site for anandamide synthesis and hydrolysis: differential profiles of anandamide synthase and hydrolase activities in the mouse uterus during the periimplantation period. Mol Reprod Dev (1996) 1.07
Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat. Eur J Pharmacol (2000) 1.06
Catabolism of N-acylethanolamine phospholipids by dog brain preparations. J Neurochem (1984) 1.05
Intraplantar injection of anandamide inhibits mechanically-evoked responses of spinal neurones via activation of CB2 receptors in anaesthetised rats. Neuropharmacology (2003) 1.04
The effect of the enzyme inhibitor phenylmethylsulfonyl fluoride on the pharmacological effect of anandamide in the mouse model of cannabimimetic activity. J Pharmacol Exp Ther (1997) 1.00
Peroxisome proliferator-activated receptor agonists inhibit inflammatory edema and hyperalgesia. Inflammation (2002) 1.00
Acidic nonsteroidal anti-inflammatory drugs inhibit rat brain fatty acid amide hydrolase in a pH-dependent manner. J Enzyme Inhib Med Chem (2003) 0.99
PPARgamma ligands induce prostaglandin production in vascular smooth muscle cells: indomethacin acts as a peroxisome proliferator-activated receptor-gamma antagonist. FASEB J (2003) 0.98
Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide. Eur J Pharmacol (2000) 0.97
Intrathecally applied flurbiprofen produces an endocannabinoid-dependent antinociception in the rat formalin test. Eur J Neurosci (2003) 0.96
Tandem mass spectrometric data-FAAH inhibitory activity relationships of some carbamic acid O-aryl esters. J Mass Spectrom (2004) 0.93
Selective inhibitors of fatty acid amide hydrolase relative to neuropathy target esterase and acetylcholinesterase: toxicological implications. Toxicol Appl Pharmacol (2002) 0.89
Effects of valeryl salicylate, a COX-1 inhibitor, on models of acute inflammation in mice. Pharmacol Res (2003) 0.86
A spinal mechanism for the peripheral anti-inflammatory action of indomethacin. Brain Res (2003) 0.81
Lipopolysaccharide-induced pulmonary inflammation is not accompanied by a release of anandamide into the lavage fluid or a down-regulation of the activity of fatty acid amide hydrolase. Life Sci (2004) 0.79
The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J Med Chem (2005) 2.34
CD14 regulates the dendritic cell life cycle after LPS exposure through NFAT activation. Nature (2009) 2.13
The palmitoylethanolamide family: a new class of anti-inflammatory agents? Curr Med Chem (2002) 1.92
CCM2 mediates death signaling by the TrkA receptor tyrosine kinase. Neuron (2009) 1.79
Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology (2013) 1.61
DPA-714, a new translocator protein-specific ligand: synthesis, radiofluorination, and pharmacologic characterization. J Nucl Med (2008) 1.49
Decreased serum zinc is an effect of ageing and not Alzheimer's disease. Metallomics (2014) 1.44
Glial TLR4 receptor as new target to treat neuropathic pain: efficacy of a new receptor antagonist in a model of peripheral nerve injury in mice. Glia (2008) 1.44
Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br J Pharmacol (2002) 1.40
The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Exp Cell Res (2003) 1.34
Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev (2008) 1.28
Insight into 2-phenylpyrazolo[1,5-a]pyrimidin-3-yl acetamides as peripheral benzodiazepine receptor ligands: synthesis, biological evaluation and 3D-QSAR investigation. Bioorg Med Chem (2005) 1.26
Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression. Cancer Res (2004) 1.26
A simple stopped assay for fatty acid amide hydrolase avoiding the use of a chloroform extraction phase. J Biochem Biophys Methods (2004) 1.19
A high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. Eur J Cancer (2008) 1.17
Phospho-Akt immunoreactivity in prostate cancer: relationship to disease severity and outcome, Ki67 and phosphorylated EGFR expression. PLoS One (2012) 1.14
Octamethyl-octaundecylcyclo[8]pyrrole: a promising sulfate anion extractant. J Am Chem Soc (2007) 1.13
Ala147Thr substitution in translocator protein is associated with adult separation anxiety in patients with depression. Psychiatr Genet (2009) 1.13
'Entourage' effects of N-acyl ethanolamines at human vanilloid receptors. Comparison of effects upon anandamide-induced vanilloid receptor activation and upon anandamide metabolism. Br J Pharmacol (2002) 1.12
Inhibition of fatty acid amide hydrolase, a key endocannabinoid metabolizing enzyme, by analogues of ibuprofen and indomethacin. Eur J Pharmacol (2007) 1.11
Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2-arachidonoylglycerol. Br J Pharmacol (2004) 1.10
The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol (2006) 1.10
MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res (2006) 1.09
Fatty acid amide hydrolase in prostate cancer: association with disease severity and outcome, CB1 receptor expression and regulation by IL-4. PLoS One (2010) 1.08
Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase. J Med Chem (2003) 1.07
Expression profiling in progressive stages of fumarate-hydratase deficiency: the contribution of metabolic changes to tumorigenesis. Cancer Res (2010) 1.05
Toward highly potent cancer agents by modulating the C-2 group of the arylthioindole class of tubulin polymerization inhibitors. J Med Chem (2012) 1.03
The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. Br J Pharmacol (2010) 1.01
AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain. Br J Pharmacol (2006) 0.99
The potency of the fatty acid amide hydrolase inhibitor URB597 is dependent upon the assay pH. Pharmacol Res (2006) 0.96
Glycolipids and benzylammonium lipids as novel antisepsis agents: synthesis and biological characterization. J Med Chem (2009) 0.95
Peripheral benzodiazepine receptor ligands: mitochondrial transmembrane potential depolarization and apoptosis induction in rat C6 glioma cells. Biochem Pharmacol (2004) 0.95
Esters, retroesters, and a retroamide of palmitic acid: pool for the first selective inhibitors of N-palmitoylethanolamine-selective acid amidase. J Med Chem (2003) 0.94
Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: evidence that VDM11 acts as an FAAH substrate. Br J Pharmacol (2005) 0.94
Measurement of saturable and non-saturable components of anandamide uptake into P19 embryonic carcinoma cells in the presence of fatty acid-free bovine serum albumin. Chem Phys Lipids (2005) 0.94
Radiosynthesis and evaluation of [¹¹C-carbonyl]-labeled carbamates as fatty acid amide hydrolase radiotracers for positron emission tomography. J Med Chem (2012) 0.93
High tumour cannabinoid CB1 receptor immunoreactivity negatively impacts disease-specific survival in stage II microsatellite stable colorectal cancer. PLoS One (2011) 0.93
Anxiolytic-like effects of N,N-dialkyl-2-phenylindol-3-ylglyoxylamides by modulation of translocator protein promoting neurosteroid biosynthesis. J Med Chem (2008) 0.93
Reversible, temperature-dependent, and AM404-inhibitable adsorption of anandamide to cell culture wells as a confounding factor in release experiments. Eur J Pharm Sci (2004) 0.92
On the death Trk. Dev Neurobiol (2010) 0.92
Effects of compounds that influence IK (KCNN4) channels on afterhyperpolarizing potentials, and determination of IK channel sequence, in guinea pig enteric neurons. J Neurophysiol (2007) 0.91
Benzodiazepine receptor ligands. 8: synthesis and pharmacological evaluation of new pyrazolo[5,1-c] [1,2,4]benzotriazine 5-oxide 3- and 8-disubstituted: high affinity ligands endowed with inverse-agonist pharmacological efficacy. Bioorg Med Chem (2005) 0.91
Synthesis and evaluation of paracetamol esters as novel fatty acid amide hydrolase inhibitors. J Med Chem (2010) 0.91
N,N-dialkyl-2-phenylindol-3-ylglyoxylamides. A new class of potent and selective ligands at the peripheral benzodiazepine receptor. J Med Chem (2004) 0.90
Chiral 1,3,4-oxadiazol-2-ones as highly selective FAAH inhibitors. J Med Chem (2013) 0.90
The dual fatty acid amide hydrolase/TRPV1 blocker, N-arachidonoyl-serotonin, relieves carrageenan-induced inflammation and hyperalgesia in mice. Pharmacol Res (2010) 0.89
Regulation of the slow afterhyperpolarization in enteric neurons by protein kinase A. Auton Neurosci (2006) 0.89
The cannabinoid agonist WIN 55,212-2 inhibits TNF-alpha-induced neutrophil transmigration across ECV304 cells. Eur J Pharmacol (2006) 0.89
The endocannabinoid system: current pharmacological research and therapeutic possibilities. Basic Clin Pharmacol Toxicol (2006) 0.88
Influence of the degree of unsaturation of the acyl side chain upon the interaction of analogues of 1-arachidonoylglycerol with monoacylglycerol lipase and fatty acid amide hydrolase. Biochem Biophys Res Commun (2005) 0.88
CD14 and NFAT mediate lipopolysaccharide-induced skin edema formation in mice. J Clin Invest (2012) 0.88
Endocannabinoids: a unique opportunity to develop multitarget analgesics. Pain (2013) 0.88
5'-Carbamoyl derivatives of 2'-C-methyl-purine nucleosides as selective A1 adenosine receptor agonists: affinity, efficacy, and selectivity for A1 receptor from different species. Bioorg Med Chem (2007) 0.88
Hemin and a metabolic derivative coprohemin modulate the TLR4 pathway differently through different molecular targets. Innate Immun (2010) 0.87
Acyl-based anandamide uptake inhibitors cause rapid toxicity to C6 glioma cells at pharmacologically relevant concentrations. J Neurochem (2006) 0.87
Synthesis and biological evaluation of 4-phenylquinazoline-2-carboxamides designed as a novel class of potent ligands of the translocator protein. J Med Chem (2012) 0.87
TSPO over-expression increases motility, transmigration and proliferation properties of C6 rat glioma cells. Biochim Biophys Acta (2007) 0.87
Inflammation and inflammatory agents activate protein kinase C epsilon translocation and excite guinea-pig submucosal neurons. Gastroenterology (2007) 0.86
Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors. Eur J Med Chem (2003) 0.86
Inhibition of fatty acid amide hydrolase and cyclooxygenase by the N-(3-methylpyridin-2-yl)amide derivatives of flurbiprofen and naproxen. Eur J Pharmacol (2013) 0.86
Anandamide metabolism by fatty acid amide hydrolase in intact C6 glioma cells. Increased sensitivity to inhibition by ibuprofen and flurbiprofen upon reduction of extra- but not intracellular pH. Naunyn Schmiedebergs Arch Pharmacol (2003) 0.86
WIS-NeuroMath enables versatile high throughput analyses of neuronal processes. Dev Neurobiol (2012) 0.85
Mesenchymal stem cells enhance GABAergic transmission in co-cultured hippocampal neurons. Mol Cell Neurosci (2012) 0.84
Up-regulation of A(2A) adenosine receptors by proinflammatory cytokines in rat PC12 cells. Biochem Pharmacol (2002) 0.84
Development and characterization of a promising fluorine-18 labelled radiopharmaceutical for in vivo imaging of fatty acid amide hydrolase. Bioorg Med Chem (2013) 0.84
The synthesis and biological evaluation of para-substituted phenolic N-alkyl carbamates as endocannabinoid hydrolyzing enzyme inhibitors. Eur J Med Chem (2009) 0.83
PK 11195 differentially affects cell survival in human wild-type and 18 kDa translocator protein-silenced ADF astrocytoma cells. J Cell Biochem (2008) 0.83
Inhibition of lipid a stimulated activation of human dendritic cells and macrophages by amino and hydroxylamino monosaccharides. Angew Chem Int Ed Engl (2007) 0.83
A novel assay for monoacylglycerol hydrolysis suitable for high-throughput screening. Anal Biochem (2006) 0.83
Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain: mechanisms involved. Phytother Res (2008) 0.83
Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors. Eur J Med Chem (2011) 0.82
Rimonabant, a cannabinoid CB1 receptor antagonist, attenuates mechanical allodynia and counteracts oxidative stress and nerve growth factor deficit in diabetic mice. Eur J Pharmacol (2010) 0.82
Longitudinal analysis of serum copper and ceruloplasmin in Alzheimer's disease. J Alzheimers Dis (2013) 0.82
High levels of N-palmitoylethanolamide and N-stearoylethanolamide in microdialysate samples from myalgic trapezius muscle in women. PLoS One (2011) 0.81
The cannabinoid CB2 receptor selective agonist JWH133 reduces mast cell oedema in response to compound 48/80 in vivo but not the release of beta-hexosaminidase from skin slices in vitro. Life Sci (2005) 0.81
A(2A) adenosine receptor ligands and proinflammatory cytokines induce PC 12 cell death through apoptosis. Biochem Pharmacol (2003) 0.81
Modifications of the ethanolamine head in N-palmitoylethanolamine: synthesis and evaluation of new agents interfering with the metabolism of anandamide. J Med Chem (2003) 0.81
Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists. J Med Chem (2005) 0.81
Preparation and pharmacological characterization of trans-2-amino-5(6)-fluoro-6(5)-hydroxy-1-phenyl-2,3-dihydro-1H-indenes as D2-like dopamine receptor agonists. J Med Chem (2005) 0.80
Decreased copper in Alzheimer's disease brain is predominantly in the soluble extractable fraction. Int J Alzheimers Dis (2013) 0.80
N-Morpholino- and N-diethyl-analogues of palmitoylethanolamide increase the sensitivity of transfected human vanilloid receptors to activation by anandamide without affecting fatty acid amidohydrolase activity. Bioorg Med Chem (2003) 0.80
A reversible and selective inhibitor of monoacylglycerol lipase ameliorates multiple sclerosis. Angew Chem Int Ed Engl (2014) 0.80
Thiol-ene mediated neoglycosylation of collagen patches: a preliminary study. Langmuir (2014) 0.80
Structure-activity relationship of a series of inhibitors of monoacylglycerol hydrolysis--comparison with effects upon fatty acid amide hydrolase. J Med Chem (2007) 0.80
Non-neuronal cell modulation relieves neuropathic pain: efficacy of the endogenous lipid palmitoylethanolamide. CNS Neurol Disord Drug Targets (2013) 0.80
Lipopolysaccharide-induced pulmonary inflammation is not accompanied by a release of anandamide into the lavage fluid or a down-regulation of the activity of fatty acid amide hydrolase. Life Sci (2004) 0.79
AM404 and VDM 11 non-specifically inhibit C6 glioma cell proliferation at concentrations used to block the cellular accumulation of the endocannabinoid anandamide. Arch Toxicol (2003) 0.79
Responsiveness of hepatic and cerebral cytochrome P450 in rat offspring prenatally and lactationally exposed to a reconstituted PCB mixture. Environ Toxicol (2012) 0.79
PIGA (N,N-Di-n-butyl-5-chloro-2-(4-chlorophenyl)indol-3-ylglyoxylamide), a new mitochondrial benzodiazepine-receptor ligand, induces apoptosis in C6 glioma cells. Chembiochem (2005) 0.79
Piperazinyl carbamate fatty acid amide hydrolase inhibitors and transient receptor potential channel modulators as "dual-target" analgesics. Pharmacol Res (2013) 0.79
Palvanil, a non-pungent capsaicin analogue, inhibits inflammatory and neuropathic pain with little effects on bronchopulmonary function and body temperature. Pharmacol Res (2012) 0.79